Understanding the increase in early-onset bowel cancer Fellow Kolling Institute and
Bowel Cancer Australia has committed $3 million through the NHMRC to establish the centre, supported by additional funding of $2.8 million from participating institutions and partners. ARTEMIS will be led by Associate Professor Dan Buchanan from The University of Melbourne, and will include a 22-member team across multiple disciplines, from six universities, four research institutes and four hospitals and health services.
Professor Molloy has established a bowel polyp biobank at the Kolling Institute and will contribute testing of the unique samples from people with early-onset bowel disease. His team’s expertise in the analysis of proteins and immune cells will help in the hunt for biological drivers of this form of cancer. “Collectively, the ARTEMIS team will aim to build new scientific understanding of why early onset colorectal cancer develops and establish clinical tools to help prevent and treat the disease better,” said Professor Molloy.
University of Sydney researcher Professor Mark Molloy will drive research into the rise of early- onset colorectal cancer as an investigator with the ARTEMIS Centre of Research Excellence. Early-onset colorectal cancer is a disease diagnosed in people under 50. The incidence has been rising rapidly in Australia since the 1990s, yet the cause of this rise is not understood. The centre will bring together patients and researchers from multiple institutes to study the genetic, environmental, microbial and immune factors contributing to the disease, and improve prevention, diagnosis and treatment.
Professor Mark Molloy
5
WWW.KOLLINGINSTITUTE.ORG.AU
Made with FlippingBook - professional solution for displaying marketing and sales documents online